Comorbidities, not age, linked with worse safety outcomes for Entyvio, Stelara

Patients who received Entyvio or Stelara for inflammatory bowel disease who had more comorbidities were at increased risk for hospitalization and infection, according to research published in Alimentary Pharmacology & Therapeutics.Vera E.R. Asscher, from the department of gastroenterology and hepatology at Leiden University Medical Centre in the Netherlands, and colleagues wrote that recent research has explored patient age as potential risk factor for adverse treatment outcomes in IBD, but the impact of comorbidities has not been as well-explored.“A patient’s chronologicalRead More

Share on facebook
Share on twitter
Share on linkedin